The Market for Psychedelic Drugs Gets a Big Buy Signal in Mental Health Treatment The market for psychedelic drugs to treat mental health conditions has long been stigmatized.
However, recent developments suggest that this class of medications is finally gaining recognition. Eli Lilly's announcement that it will acquire AtaiBeckley, a clinical stage maker of psychedelic drugs, for up to $3.
8 billion marks a significant milestone in the industry's increasing acceptance of psychedelics as alternatives for treating mental health conditions.